AMRX
USDAmneal Pharmaceuticals Inc. Class A Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$11.010
उच्च
$11.400
कम
$10.940
मात्रा
3.47M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
3.6B
उद्योग
Drug Manufacturers - Specialty & Generic
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
1.66M
एक्सचेंज
NMS
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Piper Sandler Reiterates Overweight on Amneal Pharmaceuticals, Raises Price Target to $13
Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals with a Overweight and raises the price target from $11 to $13.
Amneal Reports Third Quarter 2025 Financial Results
‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER,
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has tentatively approved the Company's
संबंधित स्टॉक
KEQU
Kewaunee Scientific Corporation
ONCT
Oncternal Therapeutics Inc.
OXSQ
Oxford Square Capital Corp.
DBI
Designer Brands Inc.
NSA
National Storage Affiliates Trust Common Shares of Beneficial Interest
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।